CTOs on the Move


 
Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Kleo raised $21M on 11/14/2018

Similar Companies

Pieris

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.

EIP Pharma

EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.

SCOLR Pharma Inc

SCOLR Pharma Inc is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionovo

Bionovo is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XORTX

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.